The Role of the Gastrointestinal Microbiome in Liver Disease
Liver disease is a major global health problem leading to approximately two million deaths a year. This is the consequence of a number of aetiologies, including alcohol-related, metabolic-related, viral infection, cholestatic and immune disease, leading to fibrosis and, eventually, cirrhosis. No spe...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-08-01
|
| Series: | Pathogens |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-0817/12/9/1087 |
| _version_ | 1797578187511693312 |
|---|---|
| author | Nicholas Shalaby Dorit Samocha-Bonet Nadeem O. Kaakoush Mark Danta |
| author_facet | Nicholas Shalaby Dorit Samocha-Bonet Nadeem O. Kaakoush Mark Danta |
| author_sort | Nicholas Shalaby |
| collection | DOAJ |
| description | Liver disease is a major global health problem leading to approximately two million deaths a year. This is the consequence of a number of aetiologies, including alcohol-related, metabolic-related, viral infection, cholestatic and immune disease, leading to fibrosis and, eventually, cirrhosis. No specific registered antifibrotic therapies exist to reverse liver injury, so current treatment aims at managing the underlying factors to mitigate the development of liver disease. There are bidirectional feedback loops between the liver and the rest of the gastrointestinal tract via the portal venous and biliary systems, which are mediated by microbial metabolites, specifically short-chain fatty acids (SCFAs) and secondary bile acids. The interaction between the liver and the gastrointestinal microbiome has the potential to provide a novel therapeutic modality to mitigate the progression of liver disease and its complications. This review will outline our understanding of hepatic fibrosis, liver disease, and its connection to the microbiome, which may identify potential therapeutic targets or strategies to mitigate liver disease. |
| first_indexed | 2024-03-10T22:18:32Z |
| format | Article |
| id | doaj.art-93775b3b503c411fad5de6b6bdd8392d |
| institution | Directory Open Access Journal |
| issn | 2076-0817 |
| language | English |
| last_indexed | 2024-03-10T22:18:32Z |
| publishDate | 2023-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pathogens |
| spelling | doaj.art-93775b3b503c411fad5de6b6bdd8392d2023-11-19T12:21:50ZengMDPI AGPathogens2076-08172023-08-01129108710.3390/pathogens12091087The Role of the Gastrointestinal Microbiome in Liver DiseaseNicholas Shalaby0Dorit Samocha-Bonet1Nadeem O. Kaakoush2Mark Danta3School of Clinical Medicine, Faculty of Medicine and Health, University of New South Wales, St Vincent’s Healthcare Campus, Darlinghurst, NSW 2010, AustraliaSchool of Clinical Medicine, Faculty of Medicine and Health, University of New South Wales, St Vincent’s Healthcare Campus, Darlinghurst, NSW 2010, AustraliaSchool of Biomedical Sciences, Faculty of Medicine and Health, University of New South Wales, Kensington, NSW 2033, AustraliaSchool of Clinical Medicine, Faculty of Medicine and Health, University of New South Wales, St Vincent’s Healthcare Campus, Darlinghurst, NSW 2010, AustraliaLiver disease is a major global health problem leading to approximately two million deaths a year. This is the consequence of a number of aetiologies, including alcohol-related, metabolic-related, viral infection, cholestatic and immune disease, leading to fibrosis and, eventually, cirrhosis. No specific registered antifibrotic therapies exist to reverse liver injury, so current treatment aims at managing the underlying factors to mitigate the development of liver disease. There are bidirectional feedback loops between the liver and the rest of the gastrointestinal tract via the portal venous and biliary systems, which are mediated by microbial metabolites, specifically short-chain fatty acids (SCFAs) and secondary bile acids. The interaction between the liver and the gastrointestinal microbiome has the potential to provide a novel therapeutic modality to mitigate the progression of liver disease and its complications. This review will outline our understanding of hepatic fibrosis, liver disease, and its connection to the microbiome, which may identify potential therapeutic targets or strategies to mitigate liver disease.https://www.mdpi.com/2076-0817/12/9/1087microbiomeliver fibrosiscirrhosisgastrointestinalantifibrogenic |
| spellingShingle | Nicholas Shalaby Dorit Samocha-Bonet Nadeem O. Kaakoush Mark Danta The Role of the Gastrointestinal Microbiome in Liver Disease Pathogens microbiome liver fibrosis cirrhosis gastrointestinal antifibrogenic |
| title | The Role of the Gastrointestinal Microbiome in Liver Disease |
| title_full | The Role of the Gastrointestinal Microbiome in Liver Disease |
| title_fullStr | The Role of the Gastrointestinal Microbiome in Liver Disease |
| title_full_unstemmed | The Role of the Gastrointestinal Microbiome in Liver Disease |
| title_short | The Role of the Gastrointestinal Microbiome in Liver Disease |
| title_sort | role of the gastrointestinal microbiome in liver disease |
| topic | microbiome liver fibrosis cirrhosis gastrointestinal antifibrogenic |
| url | https://www.mdpi.com/2076-0817/12/9/1087 |
| work_keys_str_mv | AT nicholasshalaby theroleofthegastrointestinalmicrobiomeinliverdisease AT doritsamochabonet theroleofthegastrointestinalmicrobiomeinliverdisease AT nadeemokaakoush theroleofthegastrointestinalmicrobiomeinliverdisease AT markdanta theroleofthegastrointestinalmicrobiomeinliverdisease AT nicholasshalaby roleofthegastrointestinalmicrobiomeinliverdisease AT doritsamochabonet roleofthegastrointestinalmicrobiomeinliverdisease AT nadeemokaakoush roleofthegastrointestinalmicrobiomeinliverdisease AT markdanta roleofthegastrointestinalmicrobiomeinliverdisease |